AFT Pharmaceuticals Equity – Specialty Pharma & OTC Drugs

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

How AI has changed who tells your company’s story

The UK government opened the Modernising Corporate Reporting (MCR) consultation in September, proposing a wholesale review of how UK companies communicate with investors and creditors: From annual reports and strategic disclosures to AGMs and digital communications.

Edison explains: The changing face of the beauty market

Audiovisual

Latest

Inside Pathos Communications: Meet the team behind the customer journey

Halyk Bank – equity proposition

Alphamin Resources’ CEO Eoin O’Driscoll on record Q3 EBITDA of c US$171m

About Edison

Corporates

Investors

Careers

AFT Pharmaceuticals (NZX: AFT)

Latest Insights

AFT Pharmaceuticals – executive interview

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

Share Price Chart

Market Data

Sector

Equity Analyst

Key Management

AFT Pharmaceuticals — Maxigesic IV’s Brazil entry, a foray into LATAM

AFT Pharmaceuticals — Expanded R&D pipeline to fuel LT growth

AFT Pharmaceuticals — Poised for international market expansion

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch

AFT Pharmaceuticals — Another R&D asset in the bag

AFT Pharmaceuticals — R&D pipeline strengthens with new candidate

AFT Pharmaceuticals — Global growth despite tough macro environment

AFT Pharmaceuticals — FDA nod for opioid alternative, upside anticipated

AFT Pharmaceuticals — Judgment clears AFT of lump sum payment claim

AFT Pharmaceuticals — Near-term goals in sight with FY23 momentum

AFT Pharmaceuticals — Maxigesic IV closer to FDA approval

AFT Pharmaceuticals — Maxigesic international momentum continues

AFT Pharmaceuticals — Big win with Maxigesic Rapid’s FDA nod

AFT Pharmaceuticals — Portfolio expansion with new in-licensing deal

AFT Pharmaceuticals — Maxigesic IV expands into East European markets

AFT Pharmaceuticals — Progressive outlook for CY23

AFT Pharmaceuticals — H123 focused on portfolio expansion

AFT Pharmaceuticals — Further studies for Maxigesic IV’s US nod

AFT Pharmaceuticals — Collaboration for developing birthmark medicine

AFT Pharmaceuticals — Pascomer falls short of FDA mandated threshold

AFT Pharmaceuticals — Expanding reach into China

AFT Pharmaceuticals — Maxigesic IV hits a roadblock in the US

AFT Pharmaceuticals — Re-acceleration leveraging its platform

AFT Pharmaceuticals — Recovery driven by strong H222

AFT Pharmaceuticals — 14% revenue growth despite COVID-19 headwinds

AFT Pharmaceuticals — Growth in the face of a challenging environment

AFT Pharmaceuticals — Growth despite COVID-19 challenges

AFT Pharmaceuticals — Solid FY20 results

AFT Pharmaceuticals — A strong start to FY20

AFT Pharmaceuticals — A licensing deal for Pascomer

AFT Pharmaceuticals — Operating profitability achieved

AFT Pharmaceuticals — Margins improving

AFT Pharmaceuticals — Strong FY18 results

AFT Pharmaceuticals — Improving profitability

AFT Pharmaceuticals — Australia and Maxigesic driving growth

AFT Pharmaceuticals — On the cusp

AFT Pharmaceuticals — Updates on several products

AFT Pharmaceuticals — Update 5 December 2016

AFT Pharmaceuticals — Update 31 May 2016

AFT Pharmaceuticals — Update 21 December 2015